Sartorius AG
Get $10 bonus on your first $100 deposit for SARTF
Get $10 bonus on your first $100 deposit for SARTF
Sartorius AG (SARTF) Stock Competitors & Peer Comparison
See (SARTF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SARTF | $226.33 | +0.00% | 15.6B | 87.72 | $2.58 | +0.27% |
| SRTOY | $20.20 | +1.48% | 192.6B | 61.86 | $0.32 | +0.22% |
| MECNY | $88.63 | +0.00% | 107.5B | N/A | N/A | N/A |
| ESLOY | $114.94 | -0.62% | 107.2B | 41.02 | $2.84 | +1.93% |
| ESLOF | $231.10 | +0.75% | 106.8B | 39.54 | $5.83 | +1.95% |
| SOAGY | $50.33 | +0.33% | 73.2B | 96.39 | $0.52 | +0.18% |
| HOCPY | $184.47 | +0.11% | 62.8B | 48.71 | $3.83 | +0.68% |
| HOCPF | $165.00 | +0.00% | 55.8B | 43.31 | $3.81 | +1.02% |
| RSMDF | $19.66 | +0.00% | 28.6B | 19.47 | $1.01 | +1.02% |
| TRUMY | $13.56 | -1.09% | 19.9B | 24.53 | $0.55 | +1.33% |
Stock Comparison
SARTF vs SRTOY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SRTOY has a market cap of 192.6B. Regarding current trading prices, SARTF is priced at $226.33, while SRTOY trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SRTOY's P/E ratio is 61.86. In terms of profitability, SARTF's ROE is +0.06%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, SARTF is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SRTOY's competition here
SARTF vs MECNY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, MECNY has a market cap of 107.5B. Regarding current trading prices, SARTF is priced at $226.33, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas MECNY's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, SARTF is more volatile compared to MECNY. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check MECNY's competition here
SARTF vs ESLOY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, ESLOY has a market cap of 107.2B. Regarding current trading prices, SARTF is priced at $226.33, while ESLOY trades at $114.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas ESLOY's P/E ratio is 41.02. In terms of profitability, SARTF's ROE is +0.06%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, SARTF is less volatile compared to ESLOY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check ESLOY's competition here
SARTF vs ESLOF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, ESLOF has a market cap of 106.8B. Regarding current trading prices, SARTF is priced at $226.33, while ESLOF trades at $231.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas ESLOF's P/E ratio is 39.54. In terms of profitability, SARTF's ROE is +0.06%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, SARTF is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check ESLOF's competition here
SARTF vs SOAGY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SOAGY has a market cap of 73.2B. Regarding current trading prices, SARTF is priced at $226.33, while SOAGY trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SOAGY's P/E ratio is 96.39. In terms of profitability, SARTF's ROE is +0.06%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, SARTF is less volatile compared to SOAGY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SOAGY's competition here
SARTF vs HOCPY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, HOCPY has a market cap of 62.8B. Regarding current trading prices, SARTF is priced at $226.33, while HOCPY trades at $184.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas HOCPY's P/E ratio is 48.71. In terms of profitability, SARTF's ROE is +0.06%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, SARTF is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check HOCPY's competition here
SARTF vs HOCPF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, HOCPF has a market cap of 55.8B. Regarding current trading prices, SARTF is priced at $226.33, while HOCPF trades at $165.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas HOCPF's P/E ratio is 43.31. In terms of profitability, SARTF's ROE is +0.06%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, SARTF is less volatile compared to HOCPF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check HOCPF's competition here
SARTF vs RSMDF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, RSMDF has a market cap of 28.6B. Regarding current trading prices, SARTF is priced at $226.33, while RSMDF trades at $19.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas RSMDF's P/E ratio is 19.47. In terms of profitability, SARTF's ROE is +0.06%, compared to RSMDF's ROE of +0.25%. Regarding short-term risk, SARTF is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check RSMDF's competition here
SARTF vs TRUMY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TRUMY has a market cap of 19.9B. Regarding current trading prices, SARTF is priced at $226.33, while TRUMY trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TRUMY's P/E ratio is 24.53. In terms of profitability, SARTF's ROE is +0.06%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, SARTF is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check TRUMY's competition here
SARTF vs SDMHF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SDMHF has a market cap of 19.5B. Regarding current trading prices, SARTF is priced at $226.33, while SDMHF trades at $200.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SDMHF's P/E ratio is 63.49. In terms of profitability, SARTF's ROE is +0.06%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, SARTF is more volatile compared to SDMHF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check SDMHF's competition here
SARTF vs TRUMF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TRUMF has a market cap of 18.3B. Regarding current trading prices, SARTF is priced at $226.33, while TRUMF trades at $12.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TRUMF's P/E ratio is 22.55. In terms of profitability, SARTF's ROE is +0.06%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, SARTF is more volatile compared to TRUMF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check TRUMF's competition here
SARTF vs SAUHF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SAUHF has a market cap of 17.8B. Regarding current trading prices, SARTF is priced at $226.33, while SAUHF trades at $104.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SAUHF's P/E ratio is 39.95. In terms of profitability, SARTF's ROE is +0.06%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, SARTF is less volatile compared to SAUHF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SAUHF's competition here
SARTF vs SAUHY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SAUHY has a market cap of 16.9B. Regarding current trading prices, SARTF is priced at $226.33, while SAUHY trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SAUHY's P/E ratio is 37.96. In terms of profitability, SARTF's ROE is +0.06%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, SARTF is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SAUHY's competition here
SARTF vs SUVPF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SUVPF has a market cap of 16.9B. Regarding current trading prices, SARTF is priced at $226.33, while SUVPF trades at $244.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SUVPF's P/E ratio is 94.40. In terms of profitability, SARTF's ROE is +0.06%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, SARTF is less volatile compared to SUVPF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SUVPF's competition here
SARTF vs CLPBY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CLPBY has a market cap of 15B. Regarding current trading prices, SARTF is priced at $226.33, while CLPBY trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CLPBY's P/E ratio is 24.70. In terms of profitability, SARTF's ROE is +0.06%, compared to CLPBY's ROE of +0.25%. Regarding short-term risk, SARTF is less volatile compared to CLPBY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check CLPBY's competition here
SARTF vs SSSGY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SSSGY has a market cap of 13.6B. Regarding current trading prices, SARTF is priced at $226.33, while SSSGY trades at $39.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SSSGY's P/E ratio is 75.87. In terms of profitability, SARTF's ROE is +0.06%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, SARTF is more volatile compared to SSSGY. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check SSSGY's competition here
SARTF vs CLPBF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CLPBF has a market cap of 13.5B. Regarding current trading prices, SARTF is priced at $226.33, while CLPBF trades at $65.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CLPBF's P/E ratio is 23.92. In terms of profitability, SARTF's ROE is +0.06%, compared to CLPBF's ROE of +0.25%. Regarding short-term risk, SARTF is less volatile compared to CLPBF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check CLPBF's competition here
SARTF vs FSPKF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, FSPKF has a market cap of 13.5B. Regarding current trading prices, SARTF is priced at $226.33, while FSPKF trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas FSPKF's P/E ratio is 52.32. In terms of profitability, SARTF's ROE is +0.06%, compared to FSPKF's ROE of +0.30%. Regarding short-term risk, SARTF is more volatile compared to FSPKF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check FSPKF's competition here
SARTF vs OCPNF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, OCPNF has a market cap of 10.5B. Regarding current trading prices, SARTF is priced at $226.33, while OCPNF trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas OCPNF's P/E ratio is 17.59. In terms of profitability, SARTF's ROE is +0.06%, compared to OCPNF's ROE of +0.11%. Regarding short-term risk, SARTF is more volatile compared to OCPNF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check OCPNF's competition here
SARTF vs CNVVY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CNVVY has a market cap of 6.1B. Regarding current trading prices, SARTF is priced at $226.33, while CNVVY trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CNVVY's P/E ratio is 36.68. In terms of profitability, SARTF's ROE is +0.06%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, SARTF is less volatile compared to CNVVY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check CNVVY's competition here
SARTF vs CNVVF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CNVVF has a market cap of 5.7B. Regarding current trading prices, SARTF is priced at $226.33, while CNVVF trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CNVVF's P/E ratio is 32.33. In terms of profitability, SARTF's ROE is +0.06%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, SARTF is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check CNVVF's competition here
SARTF vs SSMXY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SSMXY has a market cap of 5.4B. Regarding current trading prices, SARTF is priced at $226.33, while SSMXY trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SSMXY's P/E ratio is 18.49. In terms of profitability, SARTF's ROE is +0.06%, compared to SSMXY's ROE of +0.09%. Regarding short-term risk, SARTF is less volatile compared to SSMXY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SSMXY's competition here
SARTF vs AHICF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, AHICF has a market cap of 5.4B. Regarding current trading prices, SARTF is priced at $226.33, while AHICF trades at $20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas AHICF's P/E ratio is 48.50. In terms of profitability, SARTF's ROE is +0.06%, compared to AHICF's ROE of +0.12%. Regarding short-term risk, SARTF is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check AHICF's competition here
SARTF vs SSMXF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SSMXF has a market cap of 5.3B. Regarding current trading prices, SARTF is priced at $226.33, while SSMXF trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SSMXF's P/E ratio is 17.94. In terms of profitability, SARTF's ROE is +0.06%, compared to SSMXF's ROE of +0.09%. Regarding short-term risk, SARTF is less volatile compared to SSMXF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SSMXF's competition here
SARTF vs ADDLF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, ADDLF has a market cap of 4.9B. Regarding current trading prices, SARTF is priced at $226.33, while ADDLF trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, SARTF's ROE is +0.06%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, SARTF is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check ADDLF's competition here
SARTF vs YPHDF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, YPHDF has a market cap of 4.8B. Regarding current trading prices, SARTF is priced at $226.33, while YPHDF trades at $354.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas YPHDF's P/E ratio is 20.00. In terms of profitability, SARTF's ROE is +0.06%, compared to YPHDF's ROE of +0.27%. Regarding short-term risk, SARTF is less volatile compared to YPHDF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check YPHDF's competition here
SARTF vs FLMNF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, FLMNF has a market cap of 4.3B. Regarding current trading prices, SARTF is priced at $226.33, while FLMNF trades at $50.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas FLMNF's P/E ratio is 20.30. In terms of profitability, SARTF's ROE is +0.06%, compared to FLMNF's ROE of +0.20%. Regarding short-term risk, SARTF is less volatile compared to FLMNF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check FLMNF's competition here
SARTF vs FLMNY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, FLMNY has a market cap of 4.2B. Regarding current trading prices, SARTF is priced at $226.33, while FLMNY trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas FLMNY's P/E ratio is 19.87. In terms of profitability, SARTF's ROE is +0.06%, compared to FLMNY's ROE of +0.20%. Regarding short-term risk, SARTF is less volatile compared to FLMNY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check FLMNY's competition here
SARTF vs ANSLF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, ANSLF has a market cap of 3.3B. Regarding current trading prices, SARTF is priced at $226.33, while ANSLF trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, SARTF's ROE is +0.06%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, SARTF is more volatile compared to ANSLF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check ANSLF's competition here
SARTF vs ANSLY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, ANSLY has a market cap of 3B. Regarding current trading prices, SARTF is priced at $226.33, while ANSLY trades at $83.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas ANSLY's P/E ratio is 22.45. In terms of profitability, SARTF's ROE is +0.06%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, SARTF is less volatile compared to ANSLY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check ANSLY's competition here
SARTF vs CZMWF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CZMWF has a market cap of 2.7B. Regarding current trading prices, SARTF is priced at $226.33, while CZMWF trades at $30.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CZMWF's P/E ratio is 16.60. In terms of profitability, SARTF's ROE is +0.06%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, SARTF is less volatile compared to CZMWF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check CZMWF's competition here
SARTF vs CZMWY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CZMWY has a market cap of 2.7B. Regarding current trading prices, SARTF is priced at $226.33, while CZMWY trades at $30.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CZMWY's P/E ratio is 16.38. In terms of profitability, SARTF's ROE is +0.06%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, SARTF is more volatile compared to CZMWY. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check CZMWY's competition here
SARTF vs SHWGY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SHWGY has a market cap of 2.5B. Regarding current trading prices, SARTF is priced at $226.33, while SHWGY trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SHWGY's P/E ratio is 10.95. In terms of profitability, SARTF's ROE is +0.06%, compared to SHWGY's ROE of +0.07%. Regarding short-term risk, SARTF is less volatile compared to SHWGY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SHWGY's competition here
SARTF vs EKTAY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, EKTAY has a market cap of 2.3B. Regarding current trading prices, SARTF is priced at $226.33, while EKTAY trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas EKTAY's P/E ratio is -604.00. In terms of profitability, SARTF's ROE is +0.06%, compared to EKTAY's ROE of -0.00%. Regarding short-term risk, SARTF is more volatile compared to EKTAY. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check EKTAY's competition here
SARTF vs TCGGY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, SARTF is priced at $226.33, while TCGGY trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, SARTF's ROE is +0.06%, compared to TCGGY's ROE of -0.09%. Regarding short-term risk, SARTF is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check TCGGY's competition here
SARTF vs EKTAF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, EKTAF has a market cap of 2.3B. Regarding current trading prices, SARTF is priced at $226.33, while EKTAF trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas EKTAF's P/E ratio is -620.00. In terms of profitability, SARTF's ROE is +0.06%, compared to EKTAF's ROE of -0.00%. Regarding short-term risk, SARTF is more volatile compared to EKTAF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check EKTAF's competition here
SARTF vs SHWGF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SHWGF has a market cap of 2B. Regarding current trading prices, SARTF is priced at $226.33, while SHWGF trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SHWGF's P/E ratio is 9.00. In terms of profitability, SARTF's ROE is +0.06%, compared to SHWGF's ROE of +0.07%. Regarding short-term risk, SARTF is less volatile compared to SHWGF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SHWGF's competition here
SARTF vs TCHBF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TCHBF has a market cap of 2B. Regarding current trading prices, SARTF is priced at $226.33, while TCHBF trades at $156.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TCHBF's P/E ratio is -14.26. In terms of profitability, SARTF's ROE is +0.06%, compared to TCHBF's ROE of -0.09%. Regarding short-term risk, SARTF is more volatile compared to TCHBF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check TCHBF's competition here
SARTF vs BOEUF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, BOEUF has a market cap of 1.6B. Regarding current trading prices, SARTF is priced at $226.33, while BOEUF trades at $24.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas BOEUF's P/E ratio is 108.52. In terms of profitability, SARTF's ROE is +0.06%, compared to BOEUF's ROE of +0.18%. Regarding short-term risk, SARTF is less volatile compared to BOEUF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check BOEUF's competition here
SARTF vs NPRRF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, SARTF is priced at $226.33, while NPRRF trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas NPRRF's P/E ratio is 26.92. In terms of profitability, SARTF's ROE is +0.06%, compared to NPRRF's ROE of N/A. Regarding short-term risk, SARTF is less volatile compared to NPRRF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check NPRRF's competition here
SARTF vs TGLVY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TGLVY has a market cap of 1.6B. Regarding current trading prices, SARTF is priced at $226.33, while TGLVY trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TGLVY's P/E ratio is 39.55. In terms of profitability, SARTF's ROE is +0.06%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, SARTF is less volatile compared to TGLVY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check TGLVY's competition here
SARTF vs BITGF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, SARTF is priced at $226.33, while BITGF trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas BITGF's P/E ratio is 45.50. In terms of profitability, SARTF's ROE is +0.06%, compared to BITGF's ROE of +0.04%. Regarding short-term risk, SARTF is less volatile compared to BITGF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check BITGF's competition here
SARTF vs SAFLY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SAFLY has a market cap of 1.2B. Regarding current trading prices, SARTF is priced at $226.33, while SAFLY trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SAFLY's P/E ratio is 14.72. In terms of profitability, SARTF's ROE is +0.06%, compared to SAFLY's ROE of +0.12%. Regarding short-term risk, SARTF is less volatile compared to SAFLY. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SAFLY's competition here
SARTF vs PBHDF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, SARTF is priced at $226.33, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, SARTF's ROE is +0.06%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, SARTF is more volatile compared to PBHDF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check PBHDF's competition here
SARTF vs TDVXF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TDVXF has a market cap of 1B. Regarding current trading prices, SARTF is priced at $226.33, while TDVXF trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TDVXF's P/E ratio is 61.25. In terms of profitability, SARTF's ROE is +0.06%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, SARTF is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check TDVXF's competition here
SARTF vs SAFLF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SAFLF has a market cap of 906.6M. Regarding current trading prices, SARTF is priced at $226.33, while SAFLF trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SAFLF's P/E ratio is 16.50. In terms of profitability, SARTF's ROE is +0.06%, compared to SAFLF's ROE of +0.12%. Regarding short-term risk, SARTF is more volatile compared to SAFLF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check SAFLF's competition here
SARTF vs NNCSF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, NNCSF has a market cap of 850.9M. Regarding current trading prices, SARTF is priced at $226.33, while NNCSF trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas NNCSF's P/E ratio is 56.10. In terms of profitability, SARTF's ROE is +0.06%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, SARTF is more volatile compared to NNCSF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check NNCSF's competition here
SARTF vs KSRBF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, KSRBF has a market cap of 841.7M. Regarding current trading prices, SARTF is priced at $226.33, while KSRBF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, SARTF's ROE is +0.06%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, SARTF is more volatile compared to KSRBF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check KSRBF's competition here
SARTF vs HGYMF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, HGYMF has a market cap of 754.4M. Regarding current trading prices, SARTF is priced at $226.33, while HGYMF trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas HGYMF's P/E ratio is 184.16. In terms of profitability, SARTF's ROE is +0.06%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, SARTF is more volatile compared to HGYMF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check HGYMF's competition here
SARTF vs GRRMF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, GRRMF has a market cap of 713.3M. Regarding current trading prices, SARTF is priced at $226.33, while GRRMF trades at $20.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas GRRMF's P/E ratio is 26.47. In terms of profitability, SARTF's ROE is +0.06%, compared to GRRMF's ROE of +0.02%. Regarding short-term risk, SARTF is less volatile compared to GRRMF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check GRRMF's competition here
SARTF vs JNDOF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, JNDOF has a market cap of 531M. Regarding current trading prices, SARTF is priced at $226.33, while JNDOF trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, SARTF's ROE is +0.06%, compared to JNDOF's ROE of +0.29%. Regarding short-term risk, SARTF is more volatile compared to JNDOF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check JNDOF's competition here
SARTF vs SPMXF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, SARTF is priced at $226.33, while SPMXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, SARTF's ROE is +0.06%, compared to SPMXF's ROE of -0.07%. Regarding short-term risk, SARTF is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check SPMXF's competition here
SARTF vs CLHLF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, SARTF is priced at $226.33, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, SARTF's ROE is +0.06%, compared to CLHLF's ROE of +0.16%. Regarding short-term risk, SARTF is more volatile compared to CLHLF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check CLHLF's competition here
SARTF vs GUERF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, SARTF is priced at $226.33, while GUERF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas GUERF's P/E ratio is 8.19. In terms of profitability, SARTF's ROE is +0.06%, compared to GUERF's ROE of +0.04%. Regarding short-term risk, SARTF is more volatile compared to GUERF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check GUERF's competition here
SARTF vs OPSSF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, SARTF is priced at $226.33, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, SARTF's ROE is +0.06%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, SARTF is less volatile compared to OPSSF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check OPSSF's competition here
SARTF vs TSNLF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TSNLF has a market cap of 239.7M. Regarding current trading prices, SARTF is priced at $226.33, while TSNLF trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TSNLF's P/E ratio is 23.81. In terms of profitability, SARTF's ROE is +0.06%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, SARTF is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check TSNLF's competition here
SARTF vs EEOIF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, SARTF is priced at $226.33, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, SARTF's ROE is +0.06%, compared to EEOIF's ROE of N/A. Regarding short-term risk, SARTF is more volatile compared to EEOIF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check EEOIF's competition here
SARTF vs OTCFF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, OTCFF has a market cap of 16.8M. Regarding current trading prices, SARTF is priced at $226.33, while OTCFF trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas OTCFF's P/E ratio is -10.50. In terms of profitability, SARTF's ROE is +0.06%, compared to OTCFF's ROE of +1.24%. Regarding short-term risk, SARTF is more volatile compared to OTCFF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check OTCFF's competition here
SARTF vs UEEC Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, UEEC has a market cap of 12.2M. Regarding current trading prices, SARTF is priced at $226.33, while UEEC trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas UEEC's P/E ratio is -2.36. In terms of profitability, SARTF's ROE is +0.06%, compared to UEEC's ROE of +1.00%. Regarding short-term risk, SARTF is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check UEEC's competition here
SARTF vs BLMHF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, SARTF is priced at $226.33, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, SARTF's ROE is +0.06%, compared to BLMHF's ROE of N/A. Regarding short-term risk, SARTF is more volatile compared to BLMHF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check BLMHF's competition here
SARTF vs PXMVF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, SARTF is priced at $226.33, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, SARTF's ROE is +0.06%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, SARTF is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check PXMVF's competition here
SARTF vs CBSC Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, SARTF is priced at $226.33, while CBSC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CBSC's P/E ratio is -4.00. In terms of profitability, SARTF's ROE is +0.06%, compared to CBSC's ROE of +0.93%. Regarding short-term risk, SARTF is more volatile compared to CBSC. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check CBSC's competition here
SARTF vs MCDA Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, SARTF is priced at $226.33, while MCDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas MCDA's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to MCDA's ROE of N/A. Regarding short-term risk, SARTF is more volatile compared to MCDA. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check MCDA's competition here
SARTF vs GVDI Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, GVDI has a market cap of 4.2M. Regarding current trading prices, SARTF is priced at $226.33, while GVDI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas GVDI's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, SARTF is more volatile compared to GVDI. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check GVDI's competition here
SARTF vs RSCF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, RSCF has a market cap of 3.8M. Regarding current trading prices, SARTF is priced at $226.33, while RSCF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas RSCF's P/E ratio is -4.42. In terms of profitability, SARTF's ROE is +0.06%, compared to RSCF's ROE of +0.10%. Regarding short-term risk, SARTF is more volatile compared to RSCF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check RSCF's competition here
SARTF vs NSTGQ Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, SARTF is priced at $226.33, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, SARTF is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check NSTGQ's competition here
SARTF vs TUTH Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TUTH has a market cap of 2.4M. Regarding current trading prices, SARTF is priced at $226.33, while TUTH trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TUTH's P/E ratio is -0.95. In terms of profitability, SARTF's ROE is +0.06%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, SARTF is less volatile compared to TUTH. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check TUTH's competition here
SARTF vs ECIA Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, ECIA has a market cap of 1.4M. Regarding current trading prices, SARTF is priced at $226.33, while ECIA trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas ECIA's P/E ratio is -3.67. In terms of profitability, SARTF's ROE is +0.06%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, SARTF is more volatile compared to ECIA. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check ECIA's competition here
SARTF vs YBGJ Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, YBGJ has a market cap of 1.1M. Regarding current trading prices, SARTF is priced at $226.33, while YBGJ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas YBGJ's P/E ratio is -0.95. In terms of profitability, SARTF's ROE is +0.06%, compared to YBGJ's ROE of +0.38%. Regarding short-term risk, SARTF is more volatile compared to YBGJ. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check YBGJ's competition here
SARTF vs OJSY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, SARTF is priced at $226.33, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas OJSY's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to OJSY's ROE of N/A. Regarding short-term risk, SARTF is more volatile compared to OJSY. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check OJSY's competition here
SARTF vs PDMI Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, SARTF is priced at $226.33, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas PDMI's P/E ratio is -0.01. In terms of profitability, SARTF's ROE is +0.06%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, SARTF is more volatile compared to PDMI. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check PDMI's competition here
SARTF vs WHSI Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, SARTF is priced at $226.33, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas WHSI's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, SARTF is more volatile compared to WHSI. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check WHSI's competition here
SARTF vs BLFE Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, SARTF is priced at $226.33, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas BLFE's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, SARTF is more volatile compared to BLFE. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check BLFE's competition here
SARTF vs QTXB Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, SARTF is priced at $226.33, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas QTXB's P/E ratio is -0.05. In terms of profitability, SARTF's ROE is +0.06%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, SARTF is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check QTXB's competition here
SARTF vs IMTH Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, IMTH has a market cap of 89.8K. Regarding current trading prices, SARTF is priced at $226.33, while IMTH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas IMTH's P/E ratio is -0.03. In terms of profitability, SARTF's ROE is +0.06%, compared to IMTH's ROE of -0.60%. Regarding short-term risk, SARTF is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check IMTH's competition here
SARTF vs LANZ Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, LANZ has a market cap of 74.5K. Regarding current trading prices, SARTF is priced at $226.33, while LANZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas LANZ's P/E ratio is 2.70. In terms of profitability, SARTF's ROE is +0.06%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, SARTF is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check LANZ's competition here
SARTF vs CEOS Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, CEOS has a market cap of 68.9K. Regarding current trading prices, SARTF is priced at $226.33, while CEOS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas CEOS's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to CEOS's ROE of +0.40%. Regarding short-term risk, SARTF is less volatile compared to CEOS. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check CEOS's competition here
SARTF vs GMVDF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, SARTF is priced at $226.33, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas GMVDF's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, SARTF is more volatile compared to GMVDF. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check GMVDF's competition here
SARTF vs REMI Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, REMI has a market cap of 14K. Regarding current trading prices, SARTF is priced at $226.33, while REMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas REMI's P/E ratio is -0.07. In terms of profitability, SARTF's ROE is +0.06%, compared to REMI's ROE of -0.11%. Regarding short-term risk, SARTF is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check REMI's competition here
SARTF vs SDCCQ Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SDCCQ has a market cap of 13.4K. Regarding current trading prices, SARTF is priced at $226.33, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, SARTF is more volatile compared to SDCCQ. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check SDCCQ's competition here
SARTF vs MDIT Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, SARTF is priced at $226.33, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas MDIT's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, SARTF is more volatile compared to MDIT. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check MDIT's competition here
SARTF vs ASFX Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, ASFX has a market cap of 7K. Regarding current trading prices, SARTF is priced at $226.33, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas ASFX's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, SARTF is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check ASFX's competition here
SARTF vs DGEN Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, SARTF is priced at $226.33, while DGEN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas DGEN's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, SARTF is more volatile compared to DGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check DGEN's competition here
SARTF vs SVSO Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, SARTF is priced at $226.33, while SVSO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SVSO's P/E ratio is -0.01. In terms of profitability, SARTF's ROE is +0.06%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, SARTF is more volatile compared to SVSO. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check SVSO's competition here
SARTF vs LFPI Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, SARTF is priced at $226.33, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas LFPI's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, SARTF is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check LFPI's competition here
SARTF vs INND Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, INND has a market cap of 1.5K. Regarding current trading prices, SARTF is priced at $226.33, while INND trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas INND's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to INND's ROE of +0.09%. Regarding short-term risk, SARTF is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check INND's competition here
SARTF vs SEYE Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, SARTF is priced at $226.33, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SEYE's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to SEYE's ROE of N/A. Regarding short-term risk, SARTF is more volatile compared to SEYE. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check SEYE's competition here
SARTF vs BGMD Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, SARTF is priced at $226.33, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas BGMD's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, SARTF is more volatile compared to BGMD. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check BGMD's competition here
SARTF vs ADLI Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, SARTF is priced at $226.33, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas ADLI's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, SARTF is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check ADLI's competition here
SARTF vs VSMD Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, VSMD has a market cap of 802. Regarding current trading prices, SARTF is priced at $226.33, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas VSMD's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, SARTF is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check VSMD's competition here
SARTF vs TEVNF Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, SARTF is priced at $226.33, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas TEVNF's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, SARTF is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for SARTF.Check TEVNF's competition here
SARTF vs HRAL Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, HRAL has a market cap of 347. Regarding current trading prices, SARTF is priced at $226.33, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas HRAL's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to HRAL's ROE of +0.21%. Regarding short-term risk, SARTF is more volatile compared to HRAL. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check HRAL's competition here
SARTF vs MICRD Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, SARTF is priced at $226.33, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas MICRD's P/E ratio is -0.00. In terms of profitability, SARTF's ROE is +0.06%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, SARTF is more volatile compared to MICRD. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check MICRD's competition here
SARTF vs RGBOQ Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, SARTF is priced at $226.33, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, SARTF's ROE is +0.06%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, SARTF is more volatile compared to RGBOQ. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check RGBOQ's competition here
SARTF vs SECI Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, SECI has a market cap of 31. Regarding current trading prices, SARTF is priced at $226.33, while SECI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas SECI's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to SECI's ROE of -0.00%. Regarding short-term risk, SARTF is more volatile compared to SECI. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check SECI's competition here
SARTF vs VTEQ Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, SARTF is priced at $226.33, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, SARTF's ROE is +0.06%, compared to VTEQ's ROE of N/A. Regarding short-term risk, SARTF is more volatile compared to VTEQ. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check VTEQ's competition here
SARTF vs MEDVD Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, SARTF is priced at $226.33, while MEDVD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas MEDVD's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to MEDVD's ROE of N/A. Regarding short-term risk, SARTF is more volatile compared to MEDVD. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check MEDVD's competition here
SARTF vs OCPNY Comparison April 2026
SARTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SARTF stands at 15.6B. In comparison, OCPNY has a market cap of 0. Regarding current trading prices, SARTF is priced at $226.33, while OCPNY trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SARTF currently has a P/E ratio of 87.72, whereas OCPNY's P/E ratio is N/A. In terms of profitability, SARTF's ROE is +0.06%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, SARTF is more volatile compared to OCPNY. This indicates potentially higher risk in terms of short-term price fluctuations for SARTF.Check OCPNY's competition here